ArticleAnnals of hematology2025
Clinical characteristics, treatment patterns and outcomes of patients with follicular lymphoma in Colombia: a real-world evidence cohort study.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma (FL) is the second most common mature B lymphoid neoplasm. Understanding its epidemiology and clinical features is crucial for developing healthcare strategies, especially in low-and middle-income countries. This retrospective study analyzed clinical features, treatment patterns and outcomes of FL patients in a Colombian Health Maintenance Organization from 2018 to 2023. Statistical analyses were descriptive; survival was assessed using the Kaplan-Meier method. A total of 406 patients were included (mean age: 55.7 ± 13.8 years; 59.4% women). 79% of patients were classified as Ann Arbor stage III-IV, and 35% as high-risk in the FLIPI score. Most frequent first line (1 L) treatments were R-CHOP (63.5%) and R-CVP (10.8%), with 77.3% of patients achieving complete response (CR). Progression to second line (2L) therapy occurred in 30% of patients; 82% achieved CR. Most frequent 2L treatments were radiotherapy (23%), obinutuzumab-based regimens (18%) and R-Bendamustine (18%). Five-year progression-free survival was 70.4%, and overall survival at 5 and 10 years was 92% and 85%, respectively. A lower risk of death was observed in patients with low-intermediate FLIPI compared to patients with high FLIPI (HR = 0.23; 95%CI: 0.11-0.49). Patients with progression in the first 24 months (POD24) had a higher risk of mortality (HR = 6.54; 95%CI = 2.73-15.43). We report an approximation of the current status of FL in Colombia. Findings showed high response rates to initial treatment and prolonged overall survival. The presence of a high FLIPI score and POD24 were associated with an increased risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.